Sichuan Kelun-Biotech Biopharmaceutical to Present Cancer Drug Trial Results At ESMO

MT Newswires Live09-09

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said it will present its new cancer drug clinical trial results at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, according to a Monday filing with the Hong Kong bourse.

The presentation will discuss the safety and efficacy of anti-TROP2 ADC sacituzumab tirumotecan, or sac-TMT, in patients with recurrent or metastatic cervical cancer and patients with previously treated advanced endometrial carcinoma (EC) and ovarian cancer.

It will also tackle exploratory analysis of patients with or without prior PD-(L)1 inhibitors in phase 3 OptiTROP-Breast01 study of sac-TMT versus chemotherapy for previously treated advanced triple-negative breast cancer.

The pharmaceutical company's stocks were down by over 1% in the early trading.

Price (HKD): $167.30, Change: $-2.3, Percent Change: -1.36%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466495187?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-09 13:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466495187","market":"us","top_or_hot":-1,"title":"Sichuan Kelun-Biotech Biopharmaceutical to Present Cancer Drug Trial Results At ESMO","media":"MT Newswires Live","content":"<html><body><p> Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said it will present its new cancer drug clinical trial results at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, according to a Monday filing with the Hong Kong bourse.</p><p>The presentation will discuss the safety and efficacy of anti-TROP2 ADC sacituzumab tirumotecan, or sac-TMT, in patients with recurrent or metastatic cervical cancer and patients with previously treated advanced endometrial carcinoma (EC) and ovarian cancer.</p><p>It will also tackle exploratory analysis of patients with or without prior PD-(L)1 inhibitors in phase 3 OptiTROP-Breast01 study of sac-TMT versus chemotherapy for previously treated advanced triple-negative breast cancer.</p><p>The pharmaceutical company's stocks were down by over 1% in the early trading.</p><p>Price (HKD): $167.30, Change: $-2.3, Percent Change: -1.36%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Kelun-Biotech Biopharmaceutical to Present Cancer Drug Trial Results At ESMO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Kelun-Biotech Biopharmaceutical to Present Cancer Drug Trial Results At ESMO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-09 13:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said it will present its new cancer drug clinical trial results at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2466495187","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466495187","pubTimestamp":1725858337,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sichuan Kelun-Biotech Biopharmaceutical  said it will present its new cancer drug clinical trial results at the European Society for Medical Oncology  Congress 2024 in Barcelona, Spain, according to a Monday filing with the Hong Kong bourse.The presentation will discuss the safety and efficacy of anti-TROP2 ADC sacituzumab tirumotecan, or sac-TMT, in patients with recurrent or metastatic cervical cancer and patients with previously treated advanced endometrial carcinoma  and ovarian cancer.It will also tackle exploratory analysis of patients with or without prior PD-1 inhibitors in phase 3 OptiTROP-Breast01 study of sac-TMT versus chemotherapy for previously treated advanced triple-negative breast cancer.The pharmaceutical company's stocks were down by over 1% in the early trading.Price : $167.30, Change: $-2.3, Percent Change: -1.36%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物-B","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","EC":"哥伦比亚国家石油","BK4023":"应用软件","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK4107":"财产与意外伤害保险","HKD":"尚乘数科","BK4588":"碎股","L":"洛斯公司","BK4526":"热门中概股","BK4201":"综合性石油与天然气企业","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC"},"translate_title":"四川科伦生物制药将在ESMO展示癌症药物试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EC":1,"HKD":1,"L":1,"06990":0.9},"content_text":"Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said it will present its new cancer drug clinical trial results at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, according to a Monday filing with the Hong Kong bourse.The presentation will discuss the safety and efficacy of anti-TROP2 ADC sacituzumab tirumotecan, or sac-TMT, in patients with recurrent or metastatic cervical cancer and patients with previously treated advanced endometrial carcinoma (EC) and ovarian cancer.It will also tackle exploratory analysis of patients with or without prior PD-(L)1 inhibitors in phase 3 OptiTROP-Breast01 study of sac-TMT versus chemotherapy for previously treated advanced triple-negative breast cancer.The pharmaceutical company's stocks were down by over 1% in the early trading.Price (HKD): $167.30, Change: $-2.3, Percent Change: -1.36%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466495187"}